Lupus Market Snapshot: There's No Debate It's A Blockbuster Opportunity
Executive Summary
Several drug makers are working to bring the next treatment for lupus to market, and the level of interest across the industry suggests the therapeutic area represents a big commercial opportunity.
You may also be interested in...
GSK Plans Benlysta Expansion In Lupus Nephritis Based On Successful Phase III
Benlysta was an early pioneer in systemic lupus erythematosus, but GSK now plans to expand the drug into the acute area, active lupus nephritis, with a filing in 2020.
Biogen’s Phase II Lupus Success Offers An Additional Viable Pipeline Asset
While Biogen is seeking to diversify its R&D efforts, unexpected good data in two forms of lupus make internally discovered BIIB059 a viable asset to take forward, although Phase III plans are not set.
Benlysta Is Niche, But Growing, So GSK's Not Giving Up On Lupus
Sales of the BLyS inhibitor disappointed at launch, but the franchise is growing double-digits and now a new, more convenient subcutaneous formula will provide another growth opportunity.